{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T22:24:26Z","timestamp":1767219866023,"version":"3.41.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Janus Kinase (JAK) inhibitors have been successfully utilized in the clinical treatment of several rheumatologic (e.g. rheumatoid arthritis) and inflammatory diseases (e.g. hemophagocytic lymphohistiocytosis). Based on the growing evidence that moderate and severe COVID-19 infections are associated with a dysregulated inflammatory state, this class of medications has been repurposed as a potential therapy for COVID-19, an infection caused by Severe Acute Respiratory Syndrome Coronavirus 2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Three JAK inhibitors have been evaluated in human studies of COVID-19: Baricitinib, Tofacitinib, and Ruxolitinib. Most published studies are observational, but three randomized placebo-controlled double-blind trials have been completed: two large trials (<jats:italic toggle=\"yes\">N<\/jats:italic>\u200a=\u200a2,558 patients) with baricitinb demonstrated significant faster improvement in clinical status and reduction in the recovery time, as well as, significant reduction in the progression to invasive mechanical ventilation and mortality. One smaller randomized trial (<jats:italic toggle=\"yes\">N<\/jats:italic>\u200a=\u200a289) involving tofacitinib showed significant reduction in the progression to invasive ventilation or death. Notably, these three randomized placebo-controlled trials with close to 3,000 patients did not reveal any safety concerns associated with JAK inhibitors in terms of secondary infections or venous thromboembolism. Based on this high-quality evidence, both the Infectious Diseases Society of America and the National Institutes of Health guidelines recommend using baricitinib as part of the treatment approach for hospitalized patients with COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>JAK inhibitors are novel treatment agents in the field of infectious diseases. One JAK inhibitor, baricitinib has demonstrated significant clinical and survival benefits in hospitalized patients with COVID-19 in phase III randomized placebo-controlled trials. Baricitinib is already recommended for clinical practice by multiple guidelines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000000869","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T01:00:26Z","timestamp":1628211626000},"page":"493-496","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19"],"prefix":"10.1097","volume":"27","author":[{"given":"Diana F.","family":"Florescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"(Suppl 1)","key":"R1-20250729","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31138\/mjr.31.1.105","article-title":"Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors","volume":"31","author":"Bertsias","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Investig"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.16659","article-title":"Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients","volume":"189","author":"Wan","year":"2020","journal-title":"Br J Haematol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The immunology of COVID-19: is immune modulation an option for treatment?","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","article-title":"Use of baricitinib in patients with moderate to severe coronavirus disease 2019","volume":"72","author":"Titanji","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"R15-20250729","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.17357","article-title":"Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia","author":"Abizanda","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"R18-20250729","article-title":"Baricitinib plus standard of care for hospitalized adults with COVID-19","author":"Marconi","year":"2021","journal-title":"medRxiv"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"102039","DOI":"10.1016\/j.pupt.2021.102039","article-title":"Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19","volume":"69","author":"Maslennikov","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mayocpiqo.2021.03.007","article-title":"Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American Cohort","volume":"5","author":"Hayek","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"R21-20250729","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","author":"Guimaraes","year":"2021","journal-title":"N Engl J Med"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fmed.2020.00466","article-title":"Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. analysis of data collection from RESPIRE protocol","volume":"7","author":"Capochiani","year":"2020","journal-title":"Front Med"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/bjh.16979","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume":"190","author":"Innes","year":"2020","journal-title":"Br J Haematol"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.autrev.2020.102726","article-title":"Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: a pilot study","volume":"20","author":"Kaplanski","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/ejh.13480","article-title":"Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis","volume":"105","author":"Koschmieder","year":"2020","journal-title":"Eur J Haematol"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1080\/10428194.2020.1817440","article-title":"Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)","volume":"61","author":"Sammartano","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"e13401","DOI":"10.1111\/tid.13401","article-title":"Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib","volume":"23","author":"Saraceni","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R28-20250729","first-page":"1","article-title":"Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids","author":"Sarmiento","year":"2021","journal-title":"Acta Haematol"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:10:27Z","timestamp":1753819827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000000869","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"type":"print","value":"1070-5295"},{"type":"electronic","value":"1531-7072"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}